Misplaced Pages

Childhood cancer

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Redirected from Pediatric cancers)

Medical condition
Childhood cancer
Other namesPediatric cancer
A girl trying out hats to wear after chemotherapy against a Wilms' tumor
SpecialtyPediatrics, oncology

Childhood cancer is cancer in a child. About 80% of childhood cancer cases in high-income countries can be successfully treated via modern medical treatments and optimal patient care. However, only about 10% of children diagnosed with cancer reside in high-income countries where the necessary treatments and care is available. Childhood cancer represents only about 1% of all types of cancers diagnosed in children and adults, but it is often more complex than adult cancers with unique biological characteristics. Its research and treatment is very challenging and limited. For this reason, in countries that are low- and mid-income, childhood cancer is often ignored in control planning, contributing to the burden of missed opportunities for its diagnoses and management.

In the United States, an arbitrarily adopted standard of the ages used are 0–14 years inclusive, that is, up to 14 years 11.9 months of age. However, the definition of childhood cancer sometimes includes adolescents between 15 and 19 years old. Pediatric oncology is the branch of medicine concerned with the diagnosis and treatment of cancer in children.

Signs and symptoms

Leukemia

See also: Leukemia

This is the most common type of cancer during childhood, and acute lymphoblastic leukemia (ALL) is most common in children. ALL usually develops in children between the ages of 1 and 10 (it could occur at any age). This type of cancer is more prevalent in males and in white people.

Signs & Symptoms:

Frequent delayed diagnosis (early symptoms are nonspecific)

Physical examination:

Important: It is recommended that a complete blood count is obtained (CBC) if any suspicious finding arise.

Central nervous system tumors

This is the second most common malignancy diagnosed during childhood.

Signs and Symptoms

  • Ataxia
  • Other gait disturbances (hydrocephalus due to aqueduct compression)
  • Cranial nerve abnormalities as a result of brainstem compression

Hodgkin's disease

The likelihood of developing Hodgkin's disease increases during childhood and it peaks in adolescence.

Hodgkin's disease

Signs and Symptoms

  • Painless mass in the neck
  • Persistent cough secondary to a mediastinal mass
  • Less commonly: splenomegaly or enlarged axillary or inguinal lymph nodes
  • Intermittent fever
  • Drenching night sweats
  • Loss of greater than 10 percent of total body weight.
  • Anorexia
  • Fatigue
  • Pruritus
  • Persistent painless mass

Non-Hodgkin's lymphoma

Non-Hodgkin's lymphoma is more common in older children, and it is less prevalent than Hodgkin's disease.

Signs and Symptoms

If abdomen is affected

If mediastinum is affected

If head and neck masses are affected

  • Palpable mass
  • Cranial nerve palsies
  • Nasal obstruction

Neuroblastoma

This cancer is an extracranial solid tumor commonly diagnosed in childhood.  

Signs and Symptoms

  • Dysfunction of the location of the primary tumor
  • Anorexia
  • Abdominal pain
  • Distention.

Wilms' tumor

Main article: Wilms' tumor

This malignancy presents as an abdominal mass in a child.

Signs and Symptoms

Malignancies of the musculoskeletal system

A tumor that arises in the musculoskeletal system often presents as a mass, a painful extremity or, occasionally, a pathologic fracture.

Signs and Symptoms

  • Pain awakens a child at night
  • Significant extremity dysfunction (when trauma is not involved)

Genetic syndromes associated with cancer

The cause of cancer is not yet well understood. Several chromosomal disorders and constitutional syndromes are associated with it.

Learning problems

Main article: Learning problems in childhood cancer

Children with cancer are at risk for developing various cognitive or learning problems. These difficulties may be related to brain injury stemming from the cancer itself, such as a brain tumor or central nervous system metastasis or from side effects of cancer treatments such as chemotherapy and radiation therapy. Studies have shown that chemo and radiation therapies may damage brain white matter and disrupt brain activity.

This cognitive problem is known as post-chemotherapy cognitive impairment (PCCI) or "chemo brain." This term is commonly use by cancer survivors who describe having thinking and memory problems after cancer treatment. Researchers are unsure what exactly causes chemo brain, however, they say it is likely to be linked to either the cancer itself, the cancer treatment, or be an emotional reaction to both.

This cognitive impairment is commonly noticed a few years after a child endures cancer treatment. When a childhood cancer survivor goes back to school, they might experience lower test scores, problems with memory, attention, and behavior, as well as poor hand-eye coordination and slowed development over time. Children with cancer should be monitored and assessed for these neuropsychological deficits during and after treatment. Patients with brain tumors can have cognitive impairments before treatment and radiation therapy is associated with increased risk of cognitive impairment. Parents can apply their children for special educational services at school if their cognitive learning disability affects their educational success.

Risk factors

Risk factors are any genetic or environmental exposure that increase the chances of developing a pathological condition. Some examples are age, family history, environmental factors, genetics, and economic status among others.

Demographic risk factors

  • Childhood cancer varies by age, sex, ethnicity, and race. Its incidence peaks in infancy with about 240 cases/million/year.
  • This rate decreases to 128 cases per million from 5–9 years of age, and it rises again to 220 cases/million.
  • Slight male dominance for most childhood cancers.

Environmental factors

  • High dose ionizing radiation and prior chemotherapy are accepted causes of childhood cancer, each raising risk several fold (4-7).

Genetic factors

Identified Cancer Predisposition Syndromes

  • Li-Fraumeni syndrome (TP53)
  • Hereditary breast or ovarian cancer (BRCA 1⁄2)
  • Colorectal cancer/polyposis syndromes
  • Familial retinoblastoma (RB1)
  • Familial and genetic factors are identified in 5-15% of childhood cancer cases. In <5-10% of cases, there are known environmental exposures and exogenous factors, such as prenatal exposure to tobacco, X-rays, or certain medications. For the remaining 75-90% of cases, however, the individual causes remain unknown. In most cases, as in carcinogenesis in general, the cancers are assumed to involve multiple risk factors and variables.

Aspects that make the risk factors of childhood cancer different from those seen in adult cancers include:

  • Different, and sometimes unique, exposures to environmental hazards. Children must often rely on adults to protect them from toxic environmental agents.
  • Immature physiological systems to clear or metabolize environmental substances
  • The growth and development of children in phases known as "developmental windows" result in certain "critical windows of vulnerability".

Also, a longer life expectancy in children avails for a longer time to manifest cancer processes with long latency periods, increasing the risk of developing some cancer types later in life.

Advanced parental age has been associated with increased risk of childhood cancer in the offspring. There are preventable causes of childhood malignancy, such as delivery overuse and misuse of ionizing radiation through computed tomography scans when the test is not indicated or when adult protocols are used.

Diagnosis

Types

Two girls with acute lymphocytic leukemia demonstrating intravenous access for chemotherapy.

The most common cancers in children are (childhood) leukemia (32%), brain tumors (18%), and lymphomas (11%). In 2005, 4.1 of every 100,000 young people under 20 years of age in the U.S. were diagnosed with leukemia, and 0.8 per 100,000 died from it. The number of new cases was highest among the 1–4 age group, but the number of deaths was highest among the 10–14 age group.

In 2005, 2.9 of every 100,000 people 0–19 years of age were found to have cancer of the brain or central nervous system, and 0.7 per 100,000 died from it. These cancers were found most often in children between 1 and 4 years of age, but the most deaths occurred among those aged 5–9. The main subtypes of brain and central nervous system tumors in children are: astrocytoma, brain stem glioma, craniopharyngioma, desmoplastic infantile ganglioglioma, ependymoma, high-grade glioma, medulloblastoma and atypical teratoid rhabdoid tumor.

Other, less common childhood cancer types are:

Medical specialties

Overall, treating childhood cancer requires a multidisciplinary team of doctors, nurses, social workers, therapists, and other members of the community. Here is a brief list of doctors that can treat childhood cancer:

  • Pediatric oncologist: These doctors specialize in treating childhood cancers.
  • Pediatric hematology-oncologist: These doctors specialize in treating blood diseases in children.
  • Pediatric surgeon: These doctors specialize in performing surgery on children.
  • Adolescent and young adult oncology (AYA): AYA is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer in adolescents and young adults, often defined as those aged 13–30. Studies have continuously shown that while pediatric cancer survival rates have gone up, the survival rate for adolescents and young adults has remained stagnant. Additionally, AYA helps patients with college concerns, fertility, and sense of aloneness. Studies have often shown that treating young adults with the same protocols used in pediatrics is more effective than adult-oriented treatments.

Other specialties that can assist in the treatment process include radiology, neurosurgery, orthopedic surgery, psychiatry, and endocrinology.

Treatment

Childhood cancer treatment is individualized and varies based on the severity & type of cancer. In general, treatment can include surgical resection, chemotherapy, radiation therapy, or immunotherapy.

Recent medical advances have improved our understanding of the genetic basis of childhood cancers. Treatment options are expanding, and precision medicine for childhood cancers is a rapidly growing area of research.

The side effects of chemotherapy can result in immediate and long-term treatment-related comorbidities. For children undergoing treatment for high-risk cancer, more than 80% experience life-threatening or fatal toxicity as a result of their treatment.

Psychosocial care of children with cancer is also important during the cancer journey, but the implementation of evidence-based interventions need to be further spread across pediatric cancer centers. In general, psychosocial care can include therapy with a psychologist or psychiatrist, referral to a social worker, or referral to a pastoral counselor. Family-centered psychosocial care is one approach that can be used to not only support the patient's psychosocial well-being but also support the parents and any caregivers of the patient.

Prognosis

Main article: Cancer survivor

With the advancement of new treatments for childhood cancer, 85% of individuals who had childhood cancer now survive 5 years or more. This is an increase from the mid-1970s where only 58% of children with childhood cancer survived 5 years or more. However, this survival rate is dependent on many factors such as the type of cancer, age of onset, location of the cancer, cancer stage, and if there is any genetic component to the cancer. Survival rate is also impacted by socioeconomic status and access to resources during treatment.

Since adult survivors of childhood cancer are living longer, these individuals may experience long-term complications that are associated with their cancer treatment. This can include problems with organ function, growth and development, neurocognitive function and academic achievement, and risk for additional cancers.

Premature heart disease is one example of a major long-term consequence seen in adult survivors of childhood cancer. These individuals are eight times more likely to die of heart disease than other people, and up to one quarter of the children treated for cancer develop some type of cardiac abnormality, mainly left ventricular systolic dysfunction although this may be asymptomatic or too mild to qualify for a clinical diagnosis of heart disease.

Childhood cancer survivors are also at risk of sustaining adverse effects on the kidneys and the liver. Specific cancer treatments such as cisplatin, carboplatin, and radiotherapy are known to cause kidney damage. The risk of liver damage is increased in those who have had radiotherapy to the liver and in those with other risk factors, such as a higher body mass index or chronic viral hepatitis. Certain treatments and liver surgery may also increase the risk of adverse liver effects in childhood cancer survivors.

To help monitor for these long-term consequences, a set of guidelines have been created to facilitate long term follow up for childhood, adolescent, and young adult cancer survivors. This provides guidance for healthcare professionals on how to provide high quality follow-up care and appropriate monitoring. These guidelines also help healthcare providers collaborate with oncology specialists, in order to create recommendations specific to an individual patient.

Quality of Life in survivors

Usually, Quality of Life improves with time since diagnosis, especially for children with solid tumors and hematological malignancies. Children with a CNS tumors, on the other hand, show little or no improvement over time. Quality of Life is often measured both during and after treatment, but international comparisons of both outcomes and predictors are hindered by the use of a large number of different measurements. Recently, a first step for a joint international consensus statement for measuring Quality of Life in survivors of childhood cancer has been established.

Epidemiology

Epidemiology is the study of the distribution and determinants of disease frequency in the human population and the study of how to control health problems. Internationally, the greatest variation in childhood cancer incidence occurs when comparing high-income countries to low-income ones. This may result from differences in being able to diagnose cancer, differences in risk among different ethnic or racial population subgroups, as well as differences in risk factors. An example of differing risk factors is in cases of pediatric Burkitt lymphoma, a form of non-Hodgkin lymphoma that sickens 6 to 7 children out of every 100,000 annually in parts of sub-Saharan Africa, where it is associated with a history of infection by both Epstein-Barr virus and malaria. In industrialized countries, Burkitt lymphoma is not associated with these infectious diseases. Non-Hispanic white children often have a better chance of survival compared to other racial and ethnic groups. Where an individual lives is one of the biggest determinants of health in the world, as illness and healthcare options can vary by an individual's postal code.

United States

In the United States, cancer is the second most common cause of death among children between the ages of 1 and 14 years, exceeded only by unintentional injuries such as injuries sustained in a car wreck. More than 16 out of every 100,000 children and teens in the U.S. were diagnosed with cancer, and nearly 3 of every 100,000 died from the disease. In the United States in 2012, it was estimated that there was an incidence of 12,000 new cases, and 1,300 deaths, from cancer among children 0 to 14 years of age. Cancer is the second leading cause of death in males and fourth in women under the age of 20 in the United States. The survival rate of children with cancer has improved since the late 1960s which is due to improved treatment and public health measures. The estimated proportion surviving 5 years from diagnosis increased from 77.8 percent to 82.7 percent to 85.4 percent for those diagnosed in the 1990s, 2000s, and 2010–2016.

Statistics from the 2014 American Cancer Society report:

Ages birth to 14
Sex Incidence Mortality Observed Survival %
Boys 178.0 23.3 81.3
Girls 160.1 21.1 82.0
Ages 15 to 19
Sex Incidence Mortality Observed Survival %
Boys 237.7 34.5 80.0
Girls 235.5 24.7 85.4

Note: Incidence and mortality rates are per 1,000,000 and age-adjusted to the 2000 US standard population. Observed survival percentage is based on data from 2003 to 2009.

Sub-Saharan Africa

A large number of children in Africa live in low- and middle-income countries where there is limited access to prevention or treatment of cancer. The under-five mortality rate (U5MR), a robust indicator of child health, is at 109 per 1,000 live births. The proportion of childhood cancer is higher in Africa than in developed countries, at 4.8%. Kids with cancer are disadvantaged compared to kids in developed countries; therefore their statistic for childhood cancer is higher. In sub-Saharan Africa, 10% of children die before their 5th birthday, yet it is not due to cancer; communicable diseases such as malaria, cholera, and other infections are the leading cause of death. Children with cancer are often exposed to these preventable infections and diseases. Tumor registries only cover 11% of the African population, and there is a significant absence in death registration, making the mortality database unreliable. Overall, there is a lack of reliable data, as there is limited funding and many diseases are largely unknown to this population.

United Kingdom

Cancer in children is rare in the UK, with an average of 1,800 diagnoses every year but contributing to less than 1% of all cancer-related deaths. Age is not a confounding factor in mortality from the disease in the UK. From 2014 to 2016, approximately 230 children died from cancer, with brain/CNS cancers being the most commonly fatal type.

Foundations and fundraising

This section may require cleanup to meet Misplaced Pages's quality standards. The specific problem is: needs editing for tone. Please help improve this section if you can. (June 2018) (Learn how and when to remove this message)
Part of the proceeds from the sale of yellow silage wrappings goes to childhood cancer research, Brastad, Sweden

Currently, there are various organizations whose main focus is fighting childhood cancer. Organizations focused on childhood cancer through cancer research and/or support programs include: Childhood Cancer Canada, Young Lives vs Cancer and the Children's Cancer and Leukaemia Group (in United Kingdom), Child Cancer Foundation (in New Zealand), Children's Cancer Recovery Foundation (in United States), American Childhood Cancer Organization (in United States), Childhood Cancer Support (Australia) and the Hayim Association (in Israel). Alex's Lemonade Stand Foundation allows people across the US to raise money for pediatric cancer research by organizing lemonade stands. The National Pediatric Cancer Foundation focuses on finding less toxic and more effective treatments for pediatric cancers. This foundation works with 24 different hospitals across the US in search of treatments effective in practice. Childhood Cancer International is the largest global pediatric cancer foundation. It focuses on early access to care for childhood cancers, focusing on patient support and patient advocacy.

According to estimates by experts in the field of pediatric cancer, by 2020, cancer will cost $158 million annually for both research and treatment which marks a 27% increase since 2010. Ways in which the foundations are helped by people include writing checks, collecting spare coins, bake/lemonade sales, donating portions of purchases from stores or restaurants, or Paid Time Off donations as well as auctions, bike rides, dance-a-thons. Additionally, many of the major foundations have donation buttons on their respective websites.

In addition to advancing research focusing on cancer, the foundations also offer support to families whose children are affected by the disease. The estimated total cost for one child with cancer (medical costs and lost parental wages) is $833,000. Organizations such as the National Children's Cancer Society and the Leukemia and Lymphoma Society can provide financial assistance for the costs associated with childhood cancer like medical care, home care, child care, and transportation.

Importance of family support

The emotional challenges that a parent may encounter can disrupt their child's treatment, parenting and support for the child who is ill and their siblings, and impact overall family stability. Therefore, having a support network during this time is important. Different foundations fund support groups within hospitals and online for parents and families to aid in the coping process. Targeted support for siblings of children with cancer is also warranted. Resources that account for family context, age, and gender can help siblings process cancer-related emotional reactions. These targeted resources help promote family activities and normal family functioning, while enhancing family adjustment over time.

The foundations for pediatric cancer all fall under the 501(c)3 designation which means that they are non-profit organizations that are tax-exempt. The "International Childhood Cancer Day" occurs annually on February 15.

References

  1. "EBSCO database". URAC – via Mount Sinai Hospital, New York.
  2. Botta L, Gatta G, Capocaccia R, Stiller C, Cañete A, Dal Maso L, et al. (December 2022). "Long-term survival and cure fraction estimates for childhood cancer in Europe (EUROCARE-6): results from a population-based study". The Lancet. Oncology. 23 (12): 1525–1536. doi:10.1016/s1470-2045(22)00637-4. PMID 36400102. S2CID 253602412.
  3. Moskalewicz A, Martinez B, Uleryk EM, Pechlivanoglou P, Gupta S, Nathan PC (2024-01-25). "Late mortality among 5-year survivors of childhood cancer: A systematic review and meta-analysis". Cancer. 130 (10): 1844–1857. doi:10.1002/cncr.35213. ISSN 0008-543X. PMID 38271115.
  4. Rodriguez-Galindo C, Friedrich P, Alcasabas P, Antillon F, Banavali S, Castillo L, et al. (September 2015). "Toward the Cure of All Children With Cancer Through Collaborative Efforts: Pediatric Oncology As a Global Challenge". Journal of Clinical Oncology. 33 (27): 3065–3073. doi:10.1200/JCO.2014.60.6376. PMC 4979198. PMID 26304881.
  5. "Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995". PsycEXTRA Dataset. 1999. doi:10.1037/e407432005-001. Retrieved 2022-09-17.
  6. Johnston WT, Erdmann F, Newton R, Steliarova-Foucher E, Schüz J, Roman E (April 2021). "Childhood cancer: Estimating regional and global incidence". Cancer Epidemiology. Childhood Cancer: A Global Perspective. 71 (Pt B): 101662. doi:10.1016/j.canep.2019.101662. PMID 31924557. S2CID 210150574.
  7. Bahadur G, Hindmarsh P (January 2000). "Age definitions, childhood and adolescent cancers in relation to reproductive issues". Human Reproduction. 15 (1): 227. doi:10.1093/humrep/15.1.227. PMID 10611218.
  8. ^ "Childhood Cancers: Basic Facts & Figures". Minnesota Department of Health. Archived from the original on 20 September 2017. Retrieved 1 December 2012.
  9. ^ Toretsky JA, Jenson J, Sun CC, Eskenazi AE, Campbell A, Hunger SP, et al. (June 2003). "Translocation (11;15;19): a highly specific chromosome rearrangement associated with poorly differentiated thymic carcinoma in young patients". American Journal of Clinical Oncology. 26 (3): 300–306. doi:10.1097/00000421-200306000-00019. PMID 12796605.
  10. Pollack IF (December 1994). "Brain tumors in children". The New England Journal of Medicine. 331 (22): 1500–1507. doi:10.1056/nejm199412013312207. PMID 7969301.
  11. "Hodgkin's disease". Mayo Clinical.
  12. "Non-Hodgkin's lymphoma". Mayo Clinica.
  13. Seligson MT, Surowiec SM (26 September 2022). "Superior Vena Cava Syndrome". StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. PMID 28723010.
  14. "Wilms tumor: MedlinePlus Genetics". medlineplus.gov. Retrieved 2023-09-20.
  15. Nichols KE, Li FP, Haber DA, Diller L (March 1998). "Childhood cancer predisposition: applications of molecular testing and future implications". The Journal of Pediatrics. 132 (3 Pt 1): 389–397. doi:10.1016/s0022-3476(98)70007-1. PMID 9544888.
  16. "Children Diagnosed With Cancer: Returning to School". American Cancer Society. Archived from the original on 2016-12-26. Retrieved 2012-12-18.
  17. ^ "Chemo Brain". Mayo Clinic. Mayo Foundation for Medical Education and Research. Retrieved 2019-03-19.
  18. "Late Effects of Childhood Cancer Treatment". American Cancer Society. American Cancer Society Inc. Retrieved 2019-03-19.
  19. Annett RD, Patel SK, Phipps S (December 2015). "Monitoring and Assessment of Neuropsychological Outcomes as a Standard of Care in Pediatric Oncology". Pediatric Blood & Cancer. 62 (Suppl 5): S460–S513. doi:10.1002/pbc.25749. PMID 26700917. S2CID 206339164.
  20. Irestorm E, Perrin S, Tonning Olsson I (February 2018). "Pretreatment Cognition in Patients Diagnosed With Pediatric Brain Tumors". Pediatric Neurology. 79: 28–33. doi:10.1016/j.pediatrneurol.2017.11.008. PMID 29249552.
  21. Makale MT, McDonald CR, Hattangadi-Gluth JA, Kesari S (January 2017). "Mechanisms of radiotherapy-associated cognitive disability in patients with brain tumours". Nature Reviews. Neurology. 13 (1): 52–64. doi:10.1038/nrneurol.2016.185. PMC 5805381. PMID 27982041.
  22. "Learning Problem After Treatment". Children's Oncology Group. The Children's Oncology Group. Retrieved 2019-03-19.
  23. "Risk factor". National Cancer Institute. National Institutes of Health, U.S. Department of Health and Human Services.
  24. Stovall M, Weathers R, Kasper C, Smith SA, Travis L, Ron E, et al. (July 2006). "Dose reconstruction for therapeutic and diagnostic radiation exposures: use in epidemiological studies". Radiation Research. 166 (1 Pt 2): 141–157. Bibcode:2006RadR..166..141S. doi:10.1667/rr3525.1. PMID 16808603. S2CID 9736863.
  25. Pui CH, Ribeiro RC, Hancock ML, Rivera GK, Evans WE, Raimondi SC, et al. (December 1991). "Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia". The New England Journal of Medicine. 325 (24): 1682–1687. doi:10.1016/0753-3322(92)90056-d. PMID 1944468.
  26. Lindor NM, McMaster ML, Lindor CJ, Greene MH (2008-06-01). "Concise handbook of familial cancer susceptibility syndromes - second edition". Journal of the National Cancer Institute. Monographs. 2008 (38): 3–93. doi:10.1093/jncimonographs/lgn001. PMID 18559331.
  27. ^ "Children and Cancer" (PDF). Children's Health and the Environment. A WHO Training Package for the Health Sector. World Health Organization. In turn citing:
  28. "Children and Cancer" (PDF). Children's Health and the Environment, a WHO Training Package for the Health Sector. World Health Organization. In turn citing: >Anderson LM, Diwan BA, Fear NT, Roman E (June 2000). "Critical windows of exposure for children's health: cancer in human epidemiological studies and neoplasms in experimental animal models". Environmental Health Perspectives. 108 (Suppl 3): 573–594. doi:10.1289/ehp.00108s3573. PMC 1637809. PMID 10852857.
  29. ^ "Children and Cancer" (PDF). Children's Health and the Environment. A WHO Training Package for the Health Sector. World Health Organization.
  30. Johnson KJ, Carozza SE, Chow EJ, Fox EE, Horel S, McLaughlin CC, et al. (July 2009). "Parental age and risk of childhood cancer: a pooled analysis". Epidemiology. 20 (4): 475–483. doi:10.1097/EDE.0b013e3181a5a332. PMC 2738598. PMID 19373093.
  31. "Radiology Safety - What can I do?". Image Gently. Alliance for Radiation Safety in Pediatric Imaging. Retrieved 8 February 2016.
  32. Swensen SJ, Duncan JR, Gibson R, Muething SE, LeBuhn R, Rexford J, et al. (September 2014). "An appeal for safe and appropriate imaging of children". Journal of Patient Safety. 10 (3): 121–124. doi:10.1097/PTS.0000000000000116. PMID 24988212. S2CID 33270800.
  33. Kaatsch P (June 2010). "Epidemiology of childhood cancer". Cancer Treatment Reviews. 36 (4): 277–285. doi:10.1016/j.ctrv.2010.02.003. PMID 20231056.
  34. ^ "The most common malignancies in infants, children, and adolescents". Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER 18 Regs Research Data - Total U.S., 1969-2017. National Cancer Institute, DCCPS, Surveillance Research Program. April 2019 – via UpToDate.
  35. ^ "Cancer in Children". Centers for Disease Control and Prevention. 30 July 2009. Archived from the original on 4 March 2016. Retrieved 9 September 2017.
  36. ^ "Childhood Cancer overview". American Society of Clinical Oncology (ASCO). Retrieved 1 January 2013.
  37. ^ "Who Treats Children with Cancer?". www.cancer.org. Retrieved 2022-09-12.
  38. "Treating Childhood Cancer". National Cancer Institute. U.S. Department of Health and Human Services, National Institutes of Health. 13 May 2015.
  39. "Cancer Surgery". National Cancer Institute. U.S. Department of Health and Human Services, National Institutes of Health.
  40. "Chemotherapy". National Cancer Institute. U.S. Department of Health and Human Services, National Institutes of Health.
  41. "Radiation Therapy". National Cancer Institute. U.S. Department of Health and Human Services, National Institutes of Health.
  42. "How Immunotherapy Is Used to Treat Cancer". National Cancer Institute. U.S. Department of Health and Human Services, National Institutes of Health.
  43. Sweet-Cordero EA, Biegel JA (March 2019). "The genomic landscape of pediatric cancers: Implications for diagnosis and treatment". Science. 363 (6432): 1170–1175. Bibcode:2019Sci...363.1170S. doi:10.1126/science.aaw3535. PMC 7757338. PMID 30872516.
  44. Bosse KR, Majzner RG, Mackall CL, Maris JM (March 2020). "Immune-Based Approaches for the Treatment of Pediatric Malignancies". Annual Review of Cancer Biology. 4 (1): 353–370. doi:10.1146/annurev-cancerbio-030419-033436. PMC 8189419. PMID 34113750.
  45. Adamson PC (2015). "Improving the outcome for children with cancer: Development of targeted new agents". CA. 65 (3): 212–220. doi:10.3322/caac.21273. PMC 4629487. PMID 25754421.
  46. Wiener L, Devine KA, Thompson AL (February 2020). "Advances in pediatric psychooncology". Current Opinion in Pediatrics. 32 (1): 41–47. doi:10.1097/MOP.0000000000000851. PMC 7117751. PMID 31790025.
  47. ^ Kearney JA, Salley CG, Muriel AC (December 2015). "Standards of Psychosocial Care for Parents of Children With Cancer". Pediatric Blood & Cancer. 62 (S5): S632–S683. doi:10.1002/pbc.25761. PMC 5066591. PMID 26700921.
  48. "Key Statistics for Childhood Cancers". www.cancer.org. Retrieved 2022-09-18.
  49. ^ Erdmann F, Frederiksen LE, Bonaventure A, Mader L, Hasle H, Robison LL, et al. (April 2021). "Childhood cancer: Survival, treatment modalities, late effects and improvements over time". Cancer Epidemiology. Childhood Cancer: A Global Perspective. 71 (Pt B): 101733. doi:10.1016/j.canep.2020.101733. PMID 32461035. S2CID 218976413.
  50. ^ Bhakta N, Liu Q, Ness KK, Baassiri M, Eissa H, Yeo F, et al. (December 2017). "The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE)". Lancet. 390 (10112): 2569–2582. doi:10.1016/S0140-6736(17)31610-0. PMC 5798235. PMID 28890157.
  51. ^ Hudson MM, Bhatia S, Casillas J, Landier W (September 2021). "Long-term Follow-up Care for Childhood, Adolescent, and Young Adult Cancer Survivors". Pediatrics. 148 (3): e2021053127. doi:10.1542/peds.2021-053127. PMC 9014377. PMID 34462344.
  52. ^ Lipshultz SE, Franco VI, Miller TL, Colan SD, Sallan SE (January 2015). "Cardiovascular disease in adult survivors of childhood cancer". Annual Review of Medicine. 66 (1): 161–176. doi:10.1146/annurev-med-070213-054849. PMC 5057395. PMID 25587648.
  53. Gonzalez-Manzanares R, Castillo JC, Molina JR, Ruiz-Ortiz M, Mesa D, Ojeda S, et al. (15 March 2022). "Automated Global Longitudinal Strain Assessment in Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia". Cancers. 14 (6): 1513. doi:10.3390/cancers14061513. ISSN 2072-6694. PMC 8946759. PMID 35326663.
  54. ^ Kooijmans EC, Bökenkamp A, Tjahjadi NS, Tettero JM, van Dulmen-den Broeder E, van der Pal HJ, et al. (March 2019). "Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer". The Cochrane Database of Systematic Reviews. 2019 (3): CD008944. doi:10.1002/14651858.cd008944.pub3. PMC 6410614. PMID 30855726.
  55. ^ Mulder RL, Bresters D, Van den Hof M, Koot BG, Castellino SM, Loke YK, et al. (April 2019). "Hepatic late adverse effects after antineoplastic treatment for childhood cancer". The Cochrane Database of Systematic Reviews. 4 (4): CD008205. doi:10.1002/14651858.cd008205.pub3. PMC 6463806. PMID 30985922.
  56. van Gorp M, Irestorm E, Twisk JW, Dors N, Mavinkurve-Groothuis A, Meeteren AY, et al. (September 2023). "The course of health-related quality of life after the diagnosis of childhood cancer: a national cohort study". BMC Cancer. 23 (1): 855. doi:10.1186/s12885-023-11379-z. PMC 10496372. PMID 37697253.
  57. Bakker A, Streefkerk N, Bakker A, van Gorp M, van Litsenburg R, Grootenhuis M, et al. (December 2023). "A systematic review of health-related quality of life in children and adolescents during treatment for cancer". EJC Paediatric Oncology. 2: 100134. doi:10.1016/j.ejcped.2023.100134. ISSN 2772-610X.
  58. van Kalsbeek RJ, Hudson MM, Mulder RL, Ehrhardt M, Green DM, Mulrooney DA, et al. (June 2023). "A joint international consensus statement for measuring quality of survival for patients with childhood cancer". Nature Medicine. 29 (6): 1340–1348. doi:10.1038/s41591-023-02339-y. PMID 37322119.
  59. Aschengrau A, Seage GR (2020). Essentials of Epidemiology in Public Health. Burlington, MA: Jones & Bartlett Learning. pp. 237–266.
  60. ^ "Children and Cancer". Children's Health and the Environment (PDF). A WHO Training Package for the Health Sector, World Health Organization. In turn citing: Howard SC, Metzger ML, Wilimas JA, Quintana Y, Pui CH, Robison LL, et al. (February 2008). "Childhood cancer epidemiology in low-income countries". Cancer. 112 (3): 461–72. doi:10.1002/cncr.23205. PMID 18072274. S2CID 29249749.
  61. "Viral Cancers: Epstein-Barr virus". World Health Organization Initiative for Vaccine Research. Archived from the original on March 24, 2006. Retrieved January 28, 2013.
  62. Moormann AM, Snider CJ, Chelimo K (October 2011). "The company malaria keeps: how co-infection with Epstein-Barr virus leads to endemic Burkitt lymphoma". Current Opinion in Infectious Diseases. 24 (5): 435–441. doi:10.1097/QCO.0b013e328349ac4f. PMC 3265160. PMID 21885920.
  63. "WISQARS Leading Causes of Death Reports". US Centers for Disease Control and Prevention. Retrieved 2022-12-12.
  64. "Cancer Facts & Figures" (PDF). American Cancer Society. 2011.
  65. Aiuppa L, Cartaxo T, Spicer CM (9 December 2020). "Epidemiology of Childhood Cancer in the United States". Childhood Cancer and Functional Impacts Across the Care Continuum. Washington, DC: National Academies Press (US). ISBN 978-0-309-68352-4.
  66. ^ Ward E, DeSantis C, Robbins A, Kohler B, Jemal A (Mar–Apr 2014). "Childhood and adolescent cancer statistics, 2014". CA. 64 (2): 83–103. doi:10.3322/caac.21219. PMID 24488779.
  67. Magrath I, Steliarova-Foucher E, Epelman S, Ribeiro RC, Harif M, Li CK, et al. (March 2013). "Paediatric cancer in low-income and middle-income countries". The Lancet. Oncology. 14 (3): e104–e116. doi:10.1016/s1470-2045(13)70008-1. PMID 23434340.
  68. Magrath I, Steliarova-Foucher E, Epelman S, Ribeiro RC, Harif M, Li CK, et al. (March 2013). "Paediatric cancer in low-income and middle-income countries". The Lancet. Oncology. 14 (3): e104–e116. doi:10.1016/S1470-2045(13)70008-1. PMID 23434340.
  69. UNICEF (2013). Committing to childhood survival: A promise renewed. Progress Report (PDF) (Report). Archived from the original (PDF) on 2020-09-21. Retrieved 2022-12-12.
  70. "Childhood cancer statistics". Cancer Research UK. Retrieved 27 October 2014.
  71. "Children's Cancer Recovery Foundation". Children's Cancer Recovery Foundation. Retrieved 4 May 2018.
  72. "Homepage". American Childhood Cancer Organization.
  73. "Hayim Association". Retrieved 2016-03-31.
  74. "About ALSF". Alex's Lemonade Stand Foundation. Retrieved 2 May 2018.
  75. "About NPCF". National Pediatric Cancer Foundation. Retrieved 2 May 2018.
  76. "Who We Are". Childhood Cancer International. 2015-09-16. Retrieved 2 May 2018.
  77. "Cancer costs projected to reach at least $158 billion in 2020". National Institute of Health. U.S. Department of Health and Human Services. 2015-07-23. Retrieved 2 May 2018.
  78. "Fundraising Ideas". Cure Childhood Cancer. Retrieved 2 May 2018.
  79. U.S. Environmental Protection Agency. (2017). NIEHS/EPA Children's Environmental Health and Disease Prevention Research Centers Impact Report: Protecting children's health where they live, learn, and play. EPA Publication No. EPA/600/R-17/407.
  80. "PSYCHOLOGICAL AND EMOTIONAL SUPPORT". American Childhood Cancer Organization. 2014-11-18. Retrieved 2 May 2018.
  81. ^ Van Schoors M, Sels L, Goubert L, Verhofstadt LL (May 2021). "Siblings Dealing with Pediatric Cancer: A Family- and Context-oriented Approach". Journal of Pediatric Oncology Nursing. 38 (3): 166–175. doi:10.1177/1043454221992303. hdl:1854/LU-8680415. PMID 33792425. S2CID 228925002.
  82. van Bindsbergen KL, D'Olivo P, Rozendaal MC, Merks JH, Grootenhuis MA (August 2021). "Support for families at home during childhood cancer treatment: a pilot study with Mr.V the Spaceman, a family-based activities tool". Supportive Care in Cancer. 29 (8): 4875–4884. doi:10.1007/s00520-021-05995-3. PMC 8236466. PMID 33550470.
  83. Van Schoors M, De Paepe AL, Lemiere J, Morez A, Norga K, Lambrecht K, et al. (2019). "Family Adjustment When Facing Pediatric Cancer: The Role of Parental Psychological Flexibility, Dyadic Coping, and Network Support". Frontiers in Psychology. 10: 2740. doi:10.3389/fpsyg.2019.02740. PMC 6914864. PMID 31920799.
  84. "Exemption Requirements - 501(c)(3) Organizations". IRS. Retrieved 2 May 2018.
  85. "International Childhood Cancer Day". educationscotland.gov.uk. 15 February 2013. Archived from the original on 20 November 2016. Retrieved 1 December 2012.
  86. "February 15th is International Childhood Cancer Awareness Day!!!". The Foundation for Children with Cancer (FCC). Retrieved 1 December 2012.

Public Domain This article incorporates public domain material from websites or documents of the Centers for Disease Control and Prevention.

Category: